Finding the right treatment for people living with chronic intestinal inflammation, also known as inflammatory bowel disease (IBD), might soon be getting easier.
IBD is a fairly common condition. Between 35,000 and 40,000 people in Norway live with the diagnosis. Each year approximately 3,500 people are diagnosed.
However, it has been difficult to find the right treatment since the symptoms, the course of the disease, and the effect of medication vary so much from person to person.
"The goal of our research is to develop tools that tell us what the course of the disease will look like for each patient, so that they can receive a more targeted treatment," says associate professor Ann Elisabet Østvik at the Norwegian University of Science and Technology's (NTNU) Department of Clinical and Molecular Medicine. She is also a chief physician at St. Olavs Hospital in Trondheim.
IBD Can Last for Decades
Chronic intestinal inflammation often affects young people. Typically, patients are young adults and many are already diagnosed in childhood.
No Single Treatment for Everyone
Chronic intestinal inflammation refers to two main conditions: ulcerative colitis and Crohn's disease. Ulcerative colitis affects only the colon, with superficial inflammation. Crohn's disease can affect all parts of the gastrointestinal tract, from the mouth to the anus, but occurs most commonly in the transition between the small intestine and the large intestine.
"The treatment for the two forms is more or less the same. But it's difficult to predict how the disease will develop," says Arne Kristian Sandvik, a professor in NTNU's Department of Clinical and Molecular Medicine and a chief physician at St. Olavs hospital.
Often, doctors try the mildest medications first and work up to stronger ones as needed. But what works for some patients does not necessarily work for others.
Today the health service lacks tools that could predict a probable course of the disease for each patient and the best treatment in each case.
"The goal of the IBD research group is for the research results to make it possible to divide patients with IBD into subgroups, where the course of the disease and the treatment outcomes are more similar. This division will hopefully enable us to provide more effective treatment and follow-up for each individual," says Professor Sandvik.
Breaking patients into these different groups, could for example be done according to where in the intestinal system the inflammation is, what kind of inflammation is involved and molecular differences in the inflammatory process. To get a proper overview, patients need to be tracked for a long time.
The IBD research group in Trondheim was established in 2007 at the initiative of Professor Sandvik.
This year, the research group has been granted the status of a CAG - Clinical Academic Group, which was established collaboratively by the Central Norway Regional Health Authority and NTNU. CAG is a new model in Norway, intended to bring research closer to patients and to secure research results that will benefit patients quickly.
"As the results of the research emerge, we have ongoing projects in progress, and the results flow continually," says Østvik. "As part of the newly created CAG, we're starting a project that involves collecting patient material and following patients over time, for a total of five years. This longitudinal study will be important in developing precision medicine. We generate results along the way in the course of the collection, and this material provides the basis for important research results for several years to come."
The group is highly interdisciplinary and has grown to 12 employees with backgrounds in gastroenterology, nursing, pathology, molecular biology, and cell biology. The IBD research group also includes clinicians who conduct daily treatments of a large number of IBD patients at the various partner hospitals.